NASDAQ · Drug Manufacturers - Specialty & Generic
LNTH (LNTH) Stock
$108.03
+3.06%
NASDAQ: LNTH
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
RadioMedix Appoints Brian A. Markison to Board of Directors
GlobeNewswire · Jul 15, 2026
LNTH: Lowering target price to $107.00
Argus Research · Jul 15, 2026
3 Reasons to Avoid LNTH and 1 Stock to Buy Instead
StockStory · Jul 14, 2026
1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off
StockStory · Jul 13, 2026
B. Riley Adjusts Price Target on Lantheus Holdings to $129 From $97, Maintains Buy Rating
MT Newswires · Jul 9, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held2.09%
Institutions Held116.40%
Institutions Float Held118.88%
Peer Comparison
About LNTH
LNTH is led by CEO Mary Anne Heino, employs 1,193 people, headquartered in Bedford, US, publicly traded since 2015.
LNTH stock trades at $108.03 with a market capitalization of $7.03B. The stock is valued at a price-to-earnings (P/E) ratio of 27.24, price-to-book of 5.55, price-to-sales of 3.91. Over the past 52 weeks the stock has ranged between $47.25 and $111.46, and currently trades 3.1% below its 52-week high.
On profitability, LNTH generates a return on equity (ROE) of 21.47% — well above the market average, a sign of a high-quality business, return on capital employed of 28.56%, an operating margin of 20.17%, a net profit margin of 18.05%.